Long-Term Follow-Up of the Prospective Randomized AATT Study (Autologous or Allogeneic Transplantation in Patients With Peripheral T-Cell Lymphoma) Between March 19, 2019, and February 13, 2023, 41 ...
Appropriate use of immune checkpoint inhibitors and immunotherapy differs in adults with unresectable, metastatic cutaneous ...
Discover how targeted red and near-infrared light therapies influence mitochondrial biology, cellular repair pathways, and emerging clinical treatments across multiple health systems.
Phase I and Pharmacokinetic Study of the Ribonucleotide Reductase Inhibitor, 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, Administered by 96-Hour Intravenous Continuous Infusion Virus-directed ...
Systemic therapy is often given late due to optimism bias, treatment momentum, and difficulty in end-of-life conversations, leading to increased hospitalizations and ICU admissions. MD Anderson Cancer ...
UAB is participating in a Phase I/II trial of AMT 191, a one time gene therapy designed to enable patients with classic Fabry disease to produce their own missing enzyme, potentially reducing the need ...
While lobectomy is the surgical gold standard for early-stage NSCLC, some patients will continue to need pneumonectomy to achieve radical resection. Historically, the use of adjuvant and neoadjuvant ...
Breaking News: Trump administration impacts continue to roil the life sciences sector Home » Autologous B-cell therapy WFX-001 corrects systemic α-GAL enzyme deficiency in vivo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results